Experimental cocktail targets deadly brain lymphoma

NCT ID NCT06552559

Recruiting now Disease control Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether adding the oral drug selinexor to standard chemotherapy can help people with relapsed or refractory B-cell non-Hodgkin lymphoma that has spread to the central nervous system. About 37 adults will receive the combination to find the safest dose and see if it shrinks tumors. The goal is to improve outcomes for a condition with no standard treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Selinexor (oral drug) combined with dexamethasone, ifosfamide, carboplatin, and etoposide (chemotherapy)
What this could lead to: If successful, this could offer a new treatment option for patients with hard-to-treat lymphoma that has spread to the brain or spinal cord.
What could go wrong: This is an early-phase trial with only 37 participants, so results may not apply broadly. The drug combination may cause significant side effects, and it is not expected to cure the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA RECURRENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL LYMPHOMA RECURRENT B-CELL LYMPHOMA REFRACTORY CNS METASTASES

Contacts and locations

Locations

Samsung Cancer Research Institute
RECRUITING

Seoul, 135-710, South Korea
Samsung Medical Center
RECRUITING

Seoul, 135-710, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.